CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 99 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $5,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2018 | $5,000 | -37.5% | 2,000 | 0.0% | 0.00% | – |
| Q4 2017 | $8,000 | +60.0% | 2,000 | 0.0% | 0.00% | – |
| Q3 2017 | $5,000 | -16.7% | 2,000 | 0.0% | 0.00% | – |
| Q2 2017 | $6,000 | +50.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2017 | $4,000 | +100.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | +100.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -50.0% | 2,000 | 0.0% | 0.00% | – |
| Q1 2016 | $2,000 | -60.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2015 | $5,000 | -16.7% | 2,000 | 0.0% | 0.00% | – |
| Q3 2015 | $6,000 | -25.0% | 2,000 | 0.0% | 0.00% | – |
| Q2 2015 | $8,000 | -38.5% | 2,000 | -33.3% | 0.00% | – |
| Q1 2015 | $13,000 | -7.1% | 3,000 | -45.5% | 0.00% | – |
| Q2 2014 | $14,000 | +16.7% | 5,500 | 0.0% | 0.00% | – |
| Q1 2014 | $12,000 | -29.4% | 5,500 | 0.0% | 0.00% | -100.0% |
| Q3 2013 | $17,000 | – | 5,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |